IWM
FATE icon

IHT Wealth Management’s Fate Therapeutics FATE Stock Holding History

IHT Wealth Management’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-5,524
Closed -$221K – 751
2020
Q3 		$221K Buy
+5,524
New +$193K 0.02% 581

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
JJIJ
Johnson & Johnson Innovation - JJDC New Brunswick, New Jersey $978M AUM 102.17% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

IHT Wealth Management's FATE Position: Q4 2020 in Review

IHT Wealth Management sold out of Fate Therapeutics (FATE) in Q4 2020, closing a stake of 5,524 shares — an estimated $221K sold.

IHT Wealth Management first reported a position in FATE in Q3 2020 and held it in 1 quarter. The position peaked at $221K in Q3 2020. 248 funds tracked by Wall St. Rank hold FATE as of Q4 2020.

  • IHT Wealth Management reported no remaining Fate Therapeutics position as of Q4 2020 after selling out during the quarter.
  • IHT Wealth Management sold 5,524 Fate Therapeutics shares in Q4 2020, an estimated $221K.
  • IHT Wealth Management first reported a position in Fate Therapeutics in Q3 2020 and held it in 1 quarter.
  • IHT Wealth Management's Fate Therapeutics position peaked at $221K in Q3 2020.
  • 248 funds tracked by Wall St. Rank held Fate Therapeutics as of Q4 2020.

Based on IHT Wealth Management's 13F filing for Q4 2020, filed 17 Feb 2021.